Table 4.
Severe exacerbations in the previous year and after treatment initiation with benralizumab
| Variables | Previous year (N = 27) | After treatment initiation (N = 19) |
|---|---|---|
| Severe exacerbations, mean (SD) | 4.4 (2.9) | 1.9 (1.2) |
| Annual rate of severe exacerbations | ||
| Rate per patient-year | 3.89 | 1.77 |
| Difference | 2.12 | |
| CI 95% | 0.99–3.24 | |
| p-value* | 0.002 | |
| Number of exacerbations, n (%) | ||
| 0 | 3 (11.1) | 10 (52.6) |
| 1 | 2 (7.4) | 5 (26.3) |
| 2 | 6 (22.2) | 1 (5.3) |
| ≥ 3 | 16 (59.3) | 3 (15.8) |
| Category of exacerbation, n (%) | ||
| OCS Bursts/dose increasing ≥ 3 days | 24 (88.9) | 8 (42.1) |
| Hospital admission | 5 (18.5) | 2 (10.5) |
| ED visit | 9 (33.3) | 5 (26.3) |
| Annual rate per category of exacerbation | ||
| OCS bursts/dose increasing ≥ 3 days | ||
| Rate per patient-year | 3.93 | 1.46 |
| Difference | 2.47 | |
| CI 95% | 1.40–3.54 | |
| p-value* | < 0.001 | |
| Hospital admission requirement | ||
| Rate per patient-year | 0.37 | 0.21 |
| Difference | 0.16 | |
| CI 95% | − 0.21–0.53 | |
| p-value* | 0.707 | |
| ED visit requirement | ||
| Rate per patient-year | 1.41 | 0.52 |
| Difference | 0.89 | |
| CI 95% | 0.25–1.53 | |
| p-value* | 0.034 | |
CI confidence interval, CS corticosteroids, ED emergency department, ICS inhaled corticosteroids, OCS oral corticosteroids, SD standard deviation
*Fisher’s exact test